{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:48:21Z","timestamp":1783702101164,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/25\/B\/NZ5\/01827"],"award-info":[{"award-number":["2017\/25\/B\/NZ5\/01827"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"DOI":"10.1007\/s13353-025-01022-x","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T23:57:17Z","timestamp":1760659037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Carfilzomib resistance in multiple myeloma: A comparative metabolomic analysis"],"prefix":"10.1007","author":[{"given":"Krzysztof","family":"\u017by\u0142ka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"\u0141uczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kostrzewska-Poczekaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Bednarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Bolomsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Kubicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Jarmu\u017c-Szymczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-6591","authenticated-orcid":false,"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"1022_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ajco.13459","volume":"17","author":"Y Bai","year":"2021","unstructured":"Bai Y, Su X (2021) Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac J Clin Oncol 17:29\u201335. https:\/\/doi.org\/10.1111\/ajco.13459","journal-title":"Asia Pac J Clin Oncol"},{"key":"1022_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","volume":"33","author":"S Barrio","year":"2019","unstructured":"Barrio S, St\u00fchmer T, Da-Vi\u00e1 M (2019) Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 33:447\u2013456. https:\/\/doi.org\/10.1038\/s41375-018-0216-8","journal-title":"Leukemia"},{"key":"1022_CR3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207704","volume":"104","author":"L Besse","year":"2019","unstructured":"Besse L, Besse A, Mendez-Lopez M (2019) A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica 104:e415\u2013e419. https:\/\/doi.org\/10.3324\/haematol.2018.207704","journal-title":"Haematologica"},{"key":"1022_CR4","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1172\/JCI62129","volume":"122","author":"A Carracedo","year":"2012","unstructured":"Carracedo A, Weiss D, Leliaert AK et al (2012) A metabolic prosurvival role for PML in breast cancer. J Clin Invest 122:3088\u20133100. https:\/\/doi.org\/10.1172\/JCI62129","journal-title":"J Clin Invest"},{"key":"1022_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367\u20131372. https:\/\/doi.org\/10.1038\/nbt.1511","journal-title":"Nat Biotechnol"},{"key":"1022_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18:1327\u20131337. https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8","journal-title":"Lancet Oncol"},{"key":"1022_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 32:309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"1022_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243997","author":"S Forster","year":"2023","unstructured":"Forster S, Radpour R, Ochsenbein AF (2023) Molecular and immunological mechanisms of clonal evolution in multiple myeloma. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1243997","journal-title":"Front Immunol"},{"key":"1022_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA (2023) Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood 142:4\u20134. https:\/\/doi.org\/10.1182\/blood-2023-177546","journal-title":"Blood"},{"key":"1022_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053263","volume":"8","author":"JS Gelman","year":"2013","unstructured":"Gelman JS, Sironi J, Berezniuk I et al (2013) Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS ONE 8:e53263. https:\/\/doi.org\/10.1371\/journal.pone.0053263","journal-title":"PLoS ONE"},{"key":"1022_CR11","first-page":"3280","volume":"12","author":"T Kubicki","year":"2022","unstructured":"Kubicki T, Bednarek K, Kostrzewska-Poczekaj M et al (2022) Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response. Am J Cancer Res 12:3280\u20133293","journal-title":"Am J Cancer Res"},{"issue":"12","key":"1022_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K (2023) Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(12):1281\u20131301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"key":"1022_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-12-reviews3015","volume":"3","author":"A Ledesma","year":"2002","unstructured":"Ledesma A, de Lacoba M, Rial E (2002) The mitochondrial uncoupling proteins. Genome Biol 3:reviews3015.1. https:\/\/doi.org\/10.1186\/gb-2002-3-12-reviews3015","journal-title":"Genome Biol"},{"key":"1022_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072201","volume":"27","author":"C Leonardo-Sousa","year":"2022","unstructured":"Leonardo-Sousa C, Carvalho AN, Guedes RA et al (2022) Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance. Molecules 27:2201. https:\/\/doi.org\/10.3390\/molecules27072201","journal-title":"Molecules"},{"key":"1022_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00326-6","volume":"11","author":"R Li","year":"2022","unstructured":"Li R, Ke M, Qi M et al (2022) G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt\/\u03b2-catenin pathway. Exp Hematol Oncol 11:77. https:\/\/doi.org\/10.1186\/s40164-022-00326-6","journal-title":"Exp Hematol Oncol"},{"key":"1022_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2015.12.001","journal-title":"Trends Biochem Sci"},{"key":"1022_CR17","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1182\/bloodadvances.2020002578","volume":"5","author":"BC Lipchick","year":"2021","unstructured":"Lipchick BC, Utley A, Han Z et al (2021) The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma. Blood Adv 5:1933\u20131946. https:\/\/doi.org\/10.1182\/bloodadvances.2020002578","journal-title":"Blood Adv"},{"key":"1022_CR18","doi-asserted-by":"publisher","unstructured":"Malyutina A, Sergeev P, Huber J et al (2024) Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma. bioRxiv. https:\/\/doi.org\/10.1101\/2024.05.26.595929","DOI":"10.1101\/2024.05.26.595929"},{"key":"1022_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11050275","volume":"11","author":"L Marczak","year":"2021","unstructured":"Marczak L, Idkowiak J, Tracz J et al (2021) Mass spectrometry-based lipidomics reveals differential changes in the accumulated lipid classes in chronic kidney disease. Metabolites 11:275. https:\/\/doi.org\/10.3390\/metabo11050275","journal-title":"Metabolites"},{"key":"1022_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:947\u2013959. https:\/\/doi.org\/10.1182\/blood-2012-04-403733","journal-title":"Blood"},{"key":"1022_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000339486","volume":"128","author":"D Ohgiya","year":"2012","unstructured":"Ohgiya D, Matsushita H, Onizuka M et al (2012) Association of promyelocytic leukemia protein with expression of IL-6 and resistance to treatment in multiple myeloma. Acta Haematol 128:213\u2013222. https:\/\/doi.org\/10.1159\/000339486","journal-title":"Acta Haematol"},{"key":"1022_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897862","author":"M Roman-Trufero","year":"2022","unstructured":"Roman-Trufero M, Auner HW, Edwards CM (2022) Multiple myeloma metabolism \u2013 a treasure trove of therapeutic targets? Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.897862","journal-title":"Front Immunol"},{"key":"1022_CR23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018229118","author":"P Saavedra-Garc\u00eda","year":"2021","unstructured":"Saavedra-Garc\u00eda P, Roman-Trufero M, Al-Sadah HA et al (2021) Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2018229118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1022_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899272","author":"J Schwestermann","year":"2022","unstructured":"Schwestermann J, Besse A, Driessen C, Besse L (2022) Contribution of the tumor microenvironment to metabolic changes triggering resistance of multiple myeloma to proteasome inhibitors. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.899272","journal-title":"Front Oncol"},{"key":"1022_CR25","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP, Besse L, Li N et al (2016) Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 30:2198\u20132207. https:\/\/doi.org\/10.1038\/leu.2016.102","journal-title":"Leukemia"},{"key":"1022_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.molcel.2012.08.003","volume":"48","author":"A Suraweera","year":"2012","unstructured":"Suraweera A, M\u00fcnch C, Hanssum A, Bertolotti A (2012) Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell 48:242\u2013253. https:\/\/doi.org\/10.1016\/j.molcel.2012.08.003","journal-title":"Mol Cell"},{"key":"1022_CR27","doi-asserted-by":"publisher","first-page":"35863","DOI":"10.18632\/oncotarget.16262","volume":"8","author":"RM Thompson","year":"2017","unstructured":"Thompson RM, Dytfeld D, Reyes L et al (2017) Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget 8:35863\u201335876. https:\/\/doi.org\/10.18632\/oncotarget.16262","journal-title":"Oncotarget"},{"issue":"7","key":"1022_CR28","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/s10238-023-01174-2","volume":"23","author":"R Torcasio","year":"2023","unstructured":"Torcasio R, Gallo Cantafio ME, Ikeda RK (2023) Lipid metabolic vulnerabilities of multiple myeloma. Clin Exp Med 23(7):3373\u20133390. https:\/\/doi.org\/10.1007\/s10238-023-01174-2","journal-title":"Clin Exp Med"},{"key":"1022_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397:410\u2013427. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5","journal-title":"Lancet"},{"key":"1022_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo JN, Wu Y-M, Mishler J et al (2022) The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun 13:3750. https:\/\/doi.org\/10.1038\/s41467-022-31430-0","journal-title":"Nat Commun"},{"key":"1022_CR31","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1002\/cam4.1596","volume":"7","author":"C Wu","year":"2018","unstructured":"Wu C, Yang T, Liu Y et al (2018) <scp>ARNT<\/scp>\/<scp>HIF<\/scp>\u20101\u03b2 links high\u2010risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer Med 7:3899\u20133911. https:\/\/doi.org\/10.1002\/cam4.1596","journal-title":"Cancer Med"},{"key":"1022_CR32","doi-asserted-by":"publisher","first-page":"W652","DOI":"10.1093\/nar\/gkp356","volume":"37","author":"J Xia","year":"2009","unstructured":"Xia J, Psychogios N, Young N, Wishart DS (2009) Metaboanalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res 37:W652\u2013W660. https:\/\/doi.org\/10.1093\/nar\/gkp356","journal-title":"Nucleic Acids Res"},{"key":"1022_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C et al (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175:252\u2013264. https:\/\/doi.org\/10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"key":"1022_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.891731","author":"X Yu","year":"2022","unstructured":"Yu X, Shi M, Wu Q et al (2022) Identification of UCP1 and UCP2 as potential prognostic markers in breast cancer: a study based on immunohistochemical analysis and bioinformatics. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2022.891731","journal-title":"Front Cell Dev Biol"},{"key":"1022_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-017-0169-9","volume":"5","author":"EA Zaal","year":"2017","unstructured":"Zaal EA, Wu W, Jansen G et al (2017) Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab 5:7. https:\/\/doi.org\/10.1186\/s40170-017-0169-9","journal-title":"Cancer Metab"},{"key":"1022_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5306\/wjco.v10.i9.303","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou J, Chng W-J (2019) Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World J Clin Oncol 10:303\u2013306. https:\/\/doi.org\/10.5306\/wjco.v10.i9.303","journal-title":"World J Clin Oncol"},{"key":"1022_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.100974","volume":"50","author":"X Zhou","year":"2024","unstructured":"Zhou X, He R, Hu W-X (2024) Targeting myeloma metabolism: how abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors. Neoplasia 50:100974. https:\/\/doi.org\/10.1016\/j.neo.2024.100974","journal-title":"Neoplasia"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-01022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-025-01022-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-01022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T23:57:18Z","timestamp":1760659038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-025-01022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":37,"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1007\/s13353-025-01022-x","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"value":"1234-1983","type":"print"},{"value":"2190-3883","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}